We advised the joint book-running managers and representatives of the underwriters on the offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $50 million SEC-registered follow-on offering by Coherus Oncology, Inc. of 28,600,000 shares of common stock. The common stock is listed on the Nasdaq Global Market under the symbol “CHRS.”

Coherus Oncology, Inc. is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Jared Madnick and Alexis Aguila Johnson. Partner David R. Bauer and associate Anthony Tran provided intellectual property advice. Counsel Ziyuan (Constance) Zhang and associate Alex (Ang) Gao provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post